Real World Evidence In Drug Development And Evaluation

Download Real World Evidence In Drug Development And Evaluation full books in PDF, epub, and Kindle. Read online free Real World Evidence In Drug Development And Evaluation ebook anywhere anytime directly on your device. Fast Download speed and no annoying ads. We cannot guarantee that every ebooks is available!

Real-World Evidence in Drug Development and Evaluation

Real-World Evidence in Drug Development and Evaluation
Author :
Publisher : CRC Press
Total Pages : 191
Release :
ISBN-10 : 9780429676826
ISBN-13 : 0429676824
Rating : 4/5 (824 Downloads)

Book Synopsis Real-World Evidence in Drug Development and Evaluation by : Harry Yang

Download or read book Real-World Evidence in Drug Development and Evaluation written by Harry Yang and published by CRC Press. This book was released on 2021-01-11 with total page 191 pages. Available in PDF, EPUB and Kindle. Book excerpt: Real-world evidence (RWE) has been at the forefront of pharmaceutical innovations. It plays an important role in transforming drug development from a process aimed at meeting regulatory expectations to an operating model that leverages data from disparate sources to aid business, regulatory, and healthcare decision making. Despite its many benefits, there is no single book systematically covering the latest development in the field. Written specifically for pharmaceutical practitioners, Real-World Evidence in Drug Development and Evaluation, presents a wide range of RWE applications throughout the lifecycle of drug product development. With contributions from experienced researchers in the pharmaceutical industry, the book discusses at length RWE opportunities, challenges, and solutions. Features Provides the first book and a single source of information on RWE in drug development Covers a broad array of topics on outcomes- and value-based RWE assessments Demonstrates proper Bayesian application and causal inference for real-world data (RWD) Presents real-world use cases to illustrate the use of advanced analytics and statistical methods to generate insights Offers a balanced discussion of practical RWE issues at hand and technical solutions suitable for practitioners with limited data science expertise


Real-World Evidence in Drug Development and Evaluation Related Books

Real-World Evidence in Drug Development and Evaluation
Language: en
Pages: 191
Authors: Harry Yang
Categories: Mathematics
Type: BOOK - Published: 2021-01-11 - Publisher: CRC Press

DOWNLOAD EBOOK

Real-world evidence (RWE) has been at the forefront of pharmaceutical innovations. It plays an important role in transforming drug development from a process ai
Real-World Evidence Generation and Evaluation of Therapeutics
Language: en
Pages: 103
Authors: National Academies of Sciences, Engineering, and Medicine
Categories: Medical
Type: BOOK - Published: 2017-07-05 - Publisher: National Academies Press

DOWNLOAD EBOOK

The volume and complexity of information about individual patients is greatly increasing with use of electronic records and personal devices. Potential effects
Registries for Evaluating Patient Outcomes
Language: en
Pages: 385
Authors: Agency for Healthcare Research and Quality/AHRQ
Categories: Medical
Type: BOOK - Published: 2014-04-01 - Publisher: Government Printing Office

DOWNLOAD EBOOK

This User’s Guide is intended to support the design, implementation, analysis, interpretation, and quality evaluation of registries created to increase unders
Rare Disease Drug Development
Language: en
Pages: 418
Authors: Raymond A. Huml
Categories: Medical
Type: BOOK - Published: 2021-11-08 - Publisher: Springer Nature

DOWNLOAD EBOOK

This book provides a broad overview of rare disease drug development. It offers unique insights from various perspectives, including third-party capital provide
Innovative Methods for Rare Disease Drug Development
Language: en
Pages: 321
Authors: Shein-Chung Chow
Categories: Mathematics
Type: BOOK - Published: 2020-11-11 - Publisher: CRC Press

DOWNLOAD EBOOK

In the United States, a rare disease is defined by the Orphan Drug Act as a disorder or condition that affects fewer than 200,000 persons. For the approval of "